187 related articles for article (PubMed ID: 15965967)
41. Extending levodopa action: COMT inhibition.
Martínez-Martín P; O'Brien CF
Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
[TBL] [Abstract][Full Text] [Related]
42. Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype.
Williams-Gray CH; Hampshire A; Barker RA; Owen AM
Brain; 2008 Feb; 131(Pt 2):397-408. PubMed ID: 18178571
[TBL] [Abstract][Full Text] [Related]
43. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
Najib J
Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
[TBL] [Abstract][Full Text] [Related]
44. Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone.
Jenner P; Rocha JF; Ferreira JJ; Rascol O; Soares-da-Silva P
Expert Rev Neurother; 2021 Sep; 21(9):1019-1033. PubMed ID: 34525893
[TBL] [Abstract][Full Text] [Related]
45. Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.
Hamaue N; Ogata A; Terado M; Tsuchida S; Yabe I; Sasaki H; Hirafuji M; Togashi H; Aoki T
Brain Res; 2010 Jan; 1309():110-5. PubMed ID: 19879254
[TBL] [Abstract][Full Text] [Related]
46. Association of Catechol-O-Methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in parkinson's disease in a Chinese population.
Hao H; Shao M; An J; Chen C; Feng X; Xie S; Gu Z; Chan P;
Parkinsonism Relat Disord; 2014 Oct; 20(10):1041-5. PubMed ID: 25034874
[TBL] [Abstract][Full Text] [Related]
47. Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-L-methionine and related mechanisms.
Müller T
Int Rev Neurobiol; 2010; 95():49-71. PubMed ID: 21095459
[TBL] [Abstract][Full Text] [Related]
48. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease.
Ceravolo R; Piccini P; Bailey DL; Jorga KM; Bryson H; Brooks DJ
Synapse; 2002 Mar; 43(3):201-7. PubMed ID: 11793426
[TBL] [Abstract][Full Text] [Related]
49. Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: difference in levodopa tolerance.
Rivera-Calimlim L; Reilly DK
Clin Pharmacol Ther; 1984 Jun; 35(6):804-9. PubMed ID: 6734032
[TBL] [Abstract][Full Text] [Related]
50. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
Ishihara A; Miyachi T; Nakamura T; Ohtsuki T; Kimura Y; Kihira K; Yamawaki T; Matsumoto M
Hiroshima J Med Sci; 2011 Sep; 60(3):57-62. PubMed ID: 22053701
[TBL] [Abstract][Full Text] [Related]
51. Prospecting for new catechol-
da Silva IR; Parise MR; Pereira M; da Silva RA
J Biomol Struct Dyn; 2021 Oct; 39(16):5872-5891. PubMed ID: 32691671
[TBL] [Abstract][Full Text] [Related]
52. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.
Bonifácio MJ; Sutcliffe JS; Torrão L; Wright LC; Soares-da-Silva P
Neuropharmacology; 2014 Feb; 77():334-41. PubMed ID: 24148813
[TBL] [Abstract][Full Text] [Related]
53. The correlation between genetic factors and freezing of gait in patients with Parkinson's disease.
Radojević B; Dragašević-Mišković NT; Marjanović A; Branković M; Milovanović A; Petrović I; Svetel M; Jančić I; Stanisavljević D; Milićević O; Savić MM; Kostić VS
Parkinsonism Relat Disord; 2022 May; 98():7-12. PubMed ID: 35398727
[TBL] [Abstract][Full Text] [Related]
54. Recent advances in the treatment of Parkinson's disease.
Martocci RJ
J Am Osteopath Assoc; 1975 Apr; 74(8):730-41. PubMed ID: 1092751
[No Abstract] [Full Text] [Related]
55. Catechol-O-methyltransferase (COMT) genetic variants are associated with cognitive decline in patients with Parkinson's disease.
Lin CH; Fan JY; Lin HI; Chang CW; Wu YR
Parkinsonism Relat Disord; 2018 May; 50():48-53. PubMed ID: 29439855
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects.
Vaz-da-Silva M; Loureiro AI; Nunes T; Lopes C; Rocha J; Machado R; Costa R; Torrão L; Falcão A; Wright L; Almeida L; Soares-da-Silva P
Drugs R D; 2008; 9(6):435-46. PubMed ID: 18989992
[TBL] [Abstract][Full Text] [Related]
57. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
Oertel W; Schulz JB
J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
[TBL] [Abstract][Full Text] [Related]
58. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
Lamberti P; Zoccolella S; Iliceto G; Armenise E; Fraddosio A; de Mari M; Livrea P
Mov Disord; 2005 Jan; 20(1):69-72. PubMed ID: 15390046
[TBL] [Abstract][Full Text] [Related]
59. Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease.
Guay DR
Pharmacotherapy; 1999 Jan; 19(1):6-20. PubMed ID: 9917075
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
Poewe WH; Deuschl G; Gordin A; Kultalahti ER; Leinonen M;
Acta Neurol Scand; 2002 Apr; 105(4):245-55. PubMed ID: 11939936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
